Skip to content
Publicly Available Published by De Gruyter December 13, 2013

The role of leptin/adiponectin ratio in metabolic syndrome and diabetes

Patricio López-Jaramillo, Diego Gómez-Arbeláez, Jose López-López, Cristina López-López, Javier Martínez-Ortega, Andrea Gómez-Rodríguez and Stefany Triana-Cubillos


The metabolic syndrome comprises a cluster of cardiometabolic risk factors, with insulin resistance and adiposity as its central features. Identifying individuals with metabolic syndrome is important due to its association with an increased risk of coronary heart disease and type 2 diabetes mellitus. Attention has focused on the visceral adipose tissue production of cytokines (adipokines) in metabolic syndrome and type 2 diabetes mellitus, as the levels of the anti-inflammatory adipokine adiponectin are decreased, while proinflammatory cytokines are elevated, creating a proinflammatory state associated with insulin resistance and endothelial dysfunction. In this review, we will give special attention to the role of the leptin/adiponectin ratio. We have previously demonstrated that in individuals with severe coronary artery disease, abdominal obesity was uniquely related to decreased plasma concentrations of adiponectin and increased leptin levels. Leptin/adiponectin imbalance was associated with increased waist circumference and a decreased vascular response to acetylcholine and increased vasoconstriction due to angiotensin II. Leptin and adiponectin have opposite effects on subclinical inflammation and insulin resistance. Leptin upregulates proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6; these are associated with insulin resistance and type 2 diabetes mellitus. In contrast, adiponectin has anti-inflammatory properties and downregulates the expression and release of a number of proinflammatory immune mediators. Therefore, it appears that interactions between angiotensin II and leptin/adiponectin imbalance may be important mediators of the elevated risk of developing type 2 diabetes mellitus and cardiovascular diseases associated with abdominal obesity.


Metabolic syndrome (MetS) is one of the leading global public health concerns [1]. Its prevalence varies between 15% and 40% internationally [2] and is higher in the populations of developing countries [2, 3]. MetS comprises a cluster of cardiometabolic risk factors, its central features being insulin resistance (IR) and adiposity [1, 4]. The Adult Treatment Panel III (ATPIII) criteria of the National Cholesterol and Education Program (NCEP) for MetS are the presence of three of the following characteristics: dysglycemia, low plasma high-density lipoprotein cholesterol (HDL-C), increased triglycerides (TG), elevated blood pressure, and abdominal obesity (AO) [5]. The diagnosis of MetS has been harmonized internationally using the NCEP ATPIII criteria with the notable exception of cutoffs for AO for waist circumference, which differ by ethnicity, country [5], and region [6]. MetS is of concern due to its association with an increased risk of coronary heart disease (CHD), type 2 diabetes mellitus (DM2), and other cardiometabolic diseases [7, 8]. The concept of MetS is controversial, but the higher prevalence of this cluster of metabolic alterations in Latin America suggests that it is a useful nosographic entity in the context of Latin American medicine. Therefore, it is important that physicians recognize this syndrome in order to identify a particularly high-risk population, often underestimated and undertreated [9]. We will review the possible mechanisms involved in the development of the MetS and DM2, with a particular emphasis on the role of leptin/adiponectin (L/A) ratio and its association with IR and low-degree inflammation.

Abdominal obesity and adipokine imbalance

It is well recognized that AO plays a central role in the development of MetS and contributes significantly to the progression of cardiovascular and metabolic diseases [10]. In a meta-analysis of studies assessing the impact of bodyweight on CHD, a five-unit increase in body mass index (BMI) was associated with a 29% increase in CHD risk [11]. However, it is still uncertain how much of this elevated risk is directly attributable to obesity alone and what the specific mechanisms are by which obesity (particularly AO) causes or accelerates atherogenesis.

There are a number of physiological and metabolic changes associated with obesity that may contribute to an increased risk of cardiovascular diseases (CVD). In recent years, attention has focused on the role of visceral adipose tissue due to the synthesis and release of a number of adipokines from adipocytes [12–14]. In MetS, increased visceral adipose tissue disturbs adipokine secretion and leads to a low-grade chronic inflammatory state mediated by the infiltration of macrophages into adipose tissue [14]. This inflammatory state is found to be associated with IR [15–17] and with atherosclerosis [14]. Visceral adipose tissue functions as a paracrine and an endocrine organ, secreting a number of adipokines, some of which are proinflammatory and atherogenic, such as leptin, tumor necrosis factor-α (TNF-α), resistin, interleukin-6 (IL-6), and fatty acid-binding protein 4, and others, which have anti-inflammatory, protective effects such as adiponectin [12, 13]. In MetS patients, serum adiponectin levels are decreased, while proinflammatory cytokines are elevated [18]. This imbalance in the inflammatory state leads to dysfunction of the endothelial cells, promoting the loss of their vasodilatory, antithrombotic, and antiatherogenic properties [19, 20], apparently a widespread biological response in humans [21]. The relationship between inflammation and MetS is supported by several studies [1, 18, 22], as is the association between increased visceral fat mass and MetS [23].

In this review, we pay particular attention to the interactions between AO and L/A ratio in CHD patients. We have examined these associations using an ex vivo model in which segments of internal mammary arteries were obtained from individuals with severe coronary artery disease (CAD) who subsequently underwent coronary artery bypass grafts. Patients were divided according to the presence of AO and matched by age, sex, glucose and insulin plasma levels, homeostatic model assessment (HOMA) index, lipid profile, tobacco and alcohol consumption, physical activity, and arterial blood pressure. We found that the presence of AO was uniquely related to decreased plasma concentrations of adiponectin and increased leptin levels (Figure 1) and was associated with a decreased vascular response to acetylcholine and an increased vasoconstriction in response to angiotensin II (Ang II). However, in these patients, plasma levels of other inflammatory markers evaluated, such as C-reactive protein (CRP), IL-6, and TNF-α, did not differ according to the presence or absence of AO [24]. Ang II is produced in adipocytes [25], and plasma levels of angiotensinogen and Ang II are positively associated with BMI [26]. Several studies in obese, insulin-resistant, or hypertensive animals and humans show that treatment with Ang II AT1 receptor antagonists reduces IR [27, 28]. Moreover, blocking the intracellular signals elicited by Ang II produces these effects that oppose the action of insulin on its target organs [29]. It is also proposed that the beneficial effects of AT1 receptor blockers on adipose tissue mass and IR in obesity could be related to the enhancement of adiponectin expression, the reduction of leptin expression, and the concomitant correction of the L/A imbalance [30].

Figure 1 Adiponectin, leptin and leptin/adiponectin ratio in patients with severe coronary artery disease divided by the presence of abdominal obesity.-AO: Patients without abdominal obesity; +AO: Patients with abdominal obesity. Data presented as mean. Adiponectin: μg/dL; Leptin: ng/dL. Mann-Whitney-Wilcoxon test p<0.05.

Figure 1

Adiponectin, leptin and leptin/adiponectin ratio in patients with severe coronary artery disease divided by the presence of abdominal obesity.

-AO: Patients without abdominal obesity; +AO: Patients with abdominal obesity. Data presented as mean. Adiponectin: μg/dL; Leptin: ng/dL. Mann-Whitney-Wilcoxon test p<0.05.

The role of leptin in metabolic syndrome and diabetes

Leptin has an important role in the long-term regulation of body weight. It has also been proposed as an independent risk factor for CVD and as an important link between obesity and cardiovascular risk [31, 32]. Paradoxically, markedly increased plasma leptin levels were found in obese individuals, suggesting a resistance to its effects on target organs when produced excessively [33]. Increased leptin levels were correlated both with BMI and IR in DM2 patients [34–36]. IR was found to indirectly contribute to hyperleptinemia [37], and it has been reported that the hyperinsulinemia that frequently accompanies obesity is likely to result in increased obesogenic gene expression and higher plasma leptin levels [31]. Therefore, the association between leptin and insulin may simply reflect the size of adipose tissue stores [31]. The higher leptin levels generally observed in individuals with increased plasma insulin could be partially explained by a resistance to leptin. Chronically elevated leptin levels in obesity may result in decreased responsiveness of pancreatic β-cell receptors, leading to increased insulin secretion. In turn, the resulting hyperinsulinemia may exacerbate obesity and further increase leptin levels, resulting in a diabetogenic positive feedback loop [36, 37]. In support of this proposal, Uslu et al. [35] found a close relationship between insulin and leptin levels in DM2 patients. Moreover, this group observed that leptin levels were positively correlated with TG, lipoprotein (a) [Lp (a)], Apo-A1, glucose, systolic blood pressure and diastolic blood pressure levels, and negatively with HDL-C levels in DM2 patients. Also, it has been proposed that the increased levels of leptin observed in obesity deregulates blood pressure control and results in hypertension, suggesting that leptin may also be a potential promoter of hypertension [38].

Leptin may also have a role in the immune response via the stimulation of T-helper cell proliferation and production of proinflammatory cytokines as IL-6, which induce liver CRP synthesis. In addition, leptin produced in adipocytes may directly induce IL-6 production, resulting in further upregulation of hepatic CRP production [31]. Thus, serum leptin levels may be used as an integrated marker of adiposity, IR, and vascular dysfunction useful for cardiovascular risk stratification in clinical practice.

The role of adiponectin in metabolic syndrome and cardiometabolic diseases

Adiponectin, also referred to as ACRP30 and AdipoQ [39, 40], is an adipocyte-derived hormone abundantly present in human plasma, ranging between 3 and 30 µg/mL [39]. Adiponectin levels in plasma are negatively regulated by accumulation of visceral fat [41] and are, therefore, lower in more obese individuals [42]. Adiponectin has anti-atherogenic, antidiabetic, and anti-inflammatory properties that are directly involved in obesity-related disorders. Moreover, clinical studies implicate hypoadiponectinemia in the pathogenesis of DM2 [43], CAD [44], and hypertension [45]. Hypoadiponectinemia has also been associated with left ventricular hypertrophy, which is accompanied by diastolic dysfunction [46].

Furthermore, adiponectin values may have good prognostic value in terms of CVD. High levels of adiponectin were associated with a decreased risk of CAD in male diabetic patients [47] and with cardiovascular outcomes in patients with end-stage renal failure [48]. A prospective study showed that high plasma adiponectin levels were associated with a lower risk of myocardial infarction in healthy men, independent of CRP level or glycemic status [49]. In addition, in patients with peripheral arterial disease, serum adiponectin was positively correlated with the ankle-brachial pressure index, maximum walking distance, and initial claudication distance [50], and in another study, serum levels were negatively correlated with the Fontaine stage [51].

Different pathophysiological mechanisms are implicated in the protective role of adiponectin against the genesis of cardiometabolic diseases. Adiponectin exerts an anti-inflammatory effect through the activation of its three receptors (AdipoR1, AdipoR2, and T-cadherin) [52]. The activation of AdipoR1 and R2 results in increased hepatic and skeletal muscle fatty acid oxidation, increased skeletal muscle lactate production, reduced hepatic gluconeogenesis, increased cellular glucose uptake, and inhibition of inflammation and oxidative stress [53]. In vascular endothelial cells, activation of T-cadherin is protective against oxidative stress-induced apoptosis [54]. Several mechanisms have been suggested to explain the anti-inflammatory effects of adiponectin, including direct actions on inflammatory cells, actions on NF-κB, and interactions with TNF-α [52]. It has been demonstrated that adiponectin inhibits the expression of adhesion molecules in endothelial cells and inhibits smooth muscle cell proliferation. It also inhibits the differentiation of monocytes into macrophages and the formation of foam cells and secretion of TNF-α by macrophages [55–57]. Increased adiponectin levels are related to improvement in the differentiation of preadipocytes into adipocytes, a process that is usually impaired in obese subjects [58]. In addition, adiponectin increases endothelial nitric oxide secretion [59, 60]. Therefore, adiponectin appears to be an important molecule involved in limiting the pathogenesis of obesity-linked disorders and may have potential benefits in the treatment and prevention of cardiovascular diseases. However, due to the problematic nature of supplementation of adiponectin, increasing adiponectin production may be a useful approach. The thiazolidinediones, for example, promote an increased secretion of adiponectin by activating PPAR-γ in adipocytes [61, 62]. Caloric restriction has also been shown to increase adiponectin levels and, in turn, confer resistance to myocardial ischemia-reperfusion injury [63]. Recently, a novel nonpharmacological therapeutic intervention, aged garlic extract, was found to increase adiponectin levels in individuals with MetS [64]. However, additional studies are needed to evaluate the potential benefits of increasing adiponectin in the treatment and prevention of cardiovascular and metabolic diseases.

Leptin/adiponectin ratio in metabolic syndrome and diabetes

As reviewed above, leptin and adiponectin have opposing effects on subclinical inflammation. Leptin upregulates cytokines such as TNF-α and IL-6 that are associated with IR in DM2 and is therefore considered as a proinflammatory cytokine. In contrast, adiponectin downregulates the expression and release of many proinflammatory immune mediators and exerts anti-inflammatory properties. Thorand et al. [37] suggested that leptin and adiponectin interact with each other in the modulation of DM2 risk, but that adiponectin is likely to have a stronger association with DM2 risk. Other groups also found an inverse relationship between leptin and adiponectin in DM2 patients [36] and in patients with obesity and CAD [24]. Although leptin or adiponectin were separately associated with the risk of MetS, DM2, and CAD, the association of DM2 risk with the L/A ratio was stronger than with leptin or adiponectin alone [24, 65]. These results suggest that the L/A ratio may be a useful index for IR in clinical practice and a good indicator for assessing the effectiveness of antidiabetic therapy. Indeed, it has been reported that both the calculated HOMA-IR index and the L/A ratio can be used to identify IR.

Regional differences in plasma adiponectin levels in subjects with metabolic syndrome

While in the developed world the incidence of CVD is stabilizing or decreasing [3, 66, 67] and prognosis is improving [3, 68], incidence is increasing in the developing world. These differences in the global epidemiological profile of CVD may be due to diverse geographical, environmental, demographic, socioeconomic, and ethnic characteristics [3]. We suggest that one of the explanations for these differences is that the populations of developing countries are more prone to develop cardiovascular and metabolic diseases at lower levels of AO as a result of shorter exposure times to the new lifestyles associated with modernization [69]. The shorter the exposure time, the less adapted the population and the greater the risk of an inflammatory imbalance at lower levels of AO. We propose that this phenomenon may produce epigenetic modifications in the visceral adipose tissue and, in consequence, a larger reduction in adiponectin levels in individuals in developing countries, in turn, increasing their risk of DM2 and CVD.

To evaluate this hypothesis, we reviewed studies that assessed adiponectin plasma values in subjects with MetS and then examined potential regional differences. We reviewed only English and Spanish language articles related to the association between adiponectin and MetS published since January 2002 in the Medline database. Our initial search terms were metabolic syndrome and adiponectin; we then conducted the same search as MESH terms.

We included cross sectional and cohort studies that reported adiponectin values in adults (≥18 years) with MetS. We included abstracts only when they presented unique data not already included in our review from published studies. We only included studies in which adiponectin levels were determined by ELISA and RIA. Studies were excluded from our review if they were clinical trials or case-control studies, as these types of research studies did not account for representative samples of the general population. Moreover, if the studies included postpartum women or patients with any additional condition, such as bipolar affective disorder, rheumatoid arthritis, chronic hepatitis, and chronic obstructive pulmonary disease, they were also excluded. Articles that we could not get access to were also excluded. One hundred fifty-eight articles were identified with the general search and 195 using the MESH terms, 23 of which met our inclusion criteria. Two investigators independently reviewed titles, abstracts, and full articles to determine whether studies met the inclusion criteria. Moreover, the two investigators independently abstracted data on study design; numbers of patients assessed, evaluated population, method of adiponectin quantification, and reported levels of plasma adiponectin (Table 1). Conflicting assessment between reviewers were resolved through discussion and review.

Table 1

Worldwide adiponectin levels in subjects with metabolic syndrome.

AuthorCountryAge, yearsType of studyDefinition of MetSNumber of participantsAdiponectin value, μg/mL
Adiponectin values evaluated by ELISA
 Matsuchita et al.Japan35–66Cross sectionalATP-III624 (men)5.98 (5.77–6.20)
 Kotani et al.Japan35–70Cross sectionalATP-III86 (women)7.80 (4.80–10.9)
 Tamba et al.Japan22–68Cross sectionalNHANES15207.13±3
 Kotani et al.Japan21–88Cross sectionalATP III208 (men)3.96 (2.91–6.09) (men)
470 (women)7.64 (5.11–12.18) (women)
 Seino et al.Japan30–65Cross sectionalJapanese criteria637 (men)5.7±3.1
 Kimm et al.Japan46.0±9.2 (men)Cross sectionalATP-III3820 (men)5.6±3.4 (men)
44.6±9.5 (women)2726 (women)8.6±5.3 (women)
 Nishida et al.Japan40–59Cross sectionalIDF295.15±1.79
 Ryu et al.Korea40–69Cross sectionalATP-III612 (men)6.28±0.0017 (men)
966 (women)9.62±0.0016 (women)
 Park et al.Korea54.04±11.09 (men)Cross sectionalATP-III1321 (men)6.55±3.64 (men)
54.58±10.66 (women)1525 (women)9.53±5.45 (women)
 Soo Lim et al.Korea65–84CohortATP-III175 (men)6.6±4.5 (men)
342 (women)8.8±5.6 (women)
 Ryu et al.Korea40–80Cross sectionalATP-III406 (men)3.5±2.3 (men)
383 (women)5.4±2.3 (women)
 Zhuo et al.China60–96Cross sectionalIDF953 (men)10.7 (men)
1096 (women)13.2 (women)
 Soebijanto et al.Indonesia30–60Cross sectionalATP-III33 (women)4.9±2.11
 Saltevo et al.Finland46 (mean)Cross sectionalIDF405 (men)4.9±2.7 (men)
497 (women)7.9±4.4 (women)
 Rubin et al.Germany45–65CohortATP-III110 (men)3.63±1.94
 Onat et al.Turkey37–79Cross sectionalNS11889.84±1.70
 Onat et al.Turkey37–79Cross sectionalATP-III547 (men)7.68±1.6 (men)
652 (women)10.22 ±1.7 (women)
 Liu et al.Canada50.6±11.2Cross sectionalNS686.12 (4.82–8.33)
 Devaraj et al.USA51±12Cross sectionalATP-III1235.1 (3.6–6.7)
 Hung et al.Australia22–77Cross sectionalIDF547 (men)7.9 (men)
547 (women)13.7 (women)
547 (women)13.7 (women)
 Simao et al.Brazil45.9±9.8Cross sectionalATP-III507.11 (3.19–18.22)
Adiponectin values evaluated by ELISA
 Koh et al.Korea>40Cross sectionalATP-III2471 (men)6.00 (4.32–8.53) (men)
3463 (women)10.1 (7.62–13.41) (women)
 Gannagé-Yared et al.Lebanon59.37Cross sectionalATP-III946.79±3.52

Age data are presented as a range or mean (SD), and adiponectin values are presented as mean (SD) or mean (interquartile range) according to how they were presented in the original manuscript. NS, not specified.

We found evidence of worldwide differences in adiponectin levels in subjects with MetS. While it is difficult to establish consistent regional differences (Table 1), there appears to be considerable differences between developed and developing countries within the same region. In Latin America, a Brazilian study reported adiponectin values of 7.11 µg/mL [70], and we observed levels of 5.93 µg/mL in Colombia [64], but in Australian women with MetS, the values were 13.7 µg/mL [71], while in Indonesian MetS women, the values were much lower, 4.9 µg/mL [72]. Moreover, important differences between genders were found: women showing higher levels of adiponectin than men when compared within the same country.

In the United States, a higher incidence of IR and DM2 has been reported in Latinos, compared to non-Latino whites [73, 74]. Although this observation has been attributed, at least in part, to a higher rate of obesity in Latinos [73], IR and DM2 are more prevalent in Latinos compared to whites even after controlling for weight differences [74, 75]. Moreover, decreased adiponectin levels were found in Latino compared to non-Latino White patients with CVD risk. Lower adiponectin levels in the Latino group were independent of BMI and other factors known to affect adiponectin and seemed to account for the increased IR observed in this group [76]. These findings in Latinos are similar to those from studies of adiponectin in other minority ethnic/racial groups, in that adiponectin is lower in minority groups than White populations [77]. Ethnic and racial minority groups (including Latinos) participating in the Diabetes Prevention Program study were also reported to have lower baseline adiponectin levels than non-Latino White participants [75].

In this review, we are not able to neither establish a causative association between low adiponectin and the progression of cardiovascular and metabolic diseases nor conclusively demonstrate regional differences in adiponectin levels. Our review, however, does appear to suggest a developed vs. developing country patterning of adiponectin levels. We are not able to ascertain whether the lower adiponectin values observed in subjects with MetS from developing countries were related to genetic and or environmental factors. Moreover, it is noteworthy that values of different parameters can differ from one laboratory to another; therefore, a possible bias can be present. Furthermore, the contribution of adiponectin to regional differences in cardiometabolic disease incidence has not been evaluated.

Expert opinion

The MetS, with IR and adiposity as its central features, is associated with an increased risk of CHD, DM2, and other cardiometabolic diseases. While there are a number of adipokines involved in the proinflammatory state caused by AO, interactions between Ang II and L/A imbalance, in particular, appear to have an important role in the metabolic alterations related to visceral adiposity and in the increased risk of developing DM2 and CVD associated with AO. Leptin and adiponectin have opposing effects on subclinical inflammation and IR. Leptin upregulates proinflammatory cytokines, while adiponectin has anti-inflammatory properties. Moreover, L/A imbalance is associated with increased vasoconstriction due to Ang II. To date, there are few therapeutic options to improve the L/A imbalance, and more research is warranted.


We anticipate an increasing interest in producing epigenetic modifications of visceral adipose tissue, either by pharmacological therapy or dietary interventions, with the purpose of improving the L/A imbalance in patients at elevated cardiometabolic risk. Moreover, pharmacological interventions using adiponectin supplements or analogs to examine the potential benefits of this adipokine in the treatment and prevention of cardiovascular and metabolic diseases may be conducted. The increasing burden of noncommunicable diseases in the developing world, such as in Latin America and South Asian countries and the higher sensitivity of these populations to CVD at lower levels of AO, will stimulate a particular interest in studying interactions and interventions in these populations.


  • In patients with CAD, AO is associated with decreased plasma concentrations of adiponectin and increased leptin levels and with a decreased vascular response to acetylcholine and an increased vasoconstriction in response to Ang II.

  • The regional differences in adiponectin values may have an important role in the susceptibility of certain populations to CVD. However, there is a paucity of data, and more research is required.

  • Future research should investigate potential pathways to improve the L/A ratio, especially by increasing adiponectin levels in subjects at elevated cardiometabolic risk.

  • Epigenetic modifications of the visceral adipose tissue could become an important mechanism for improving the L/A ratio.

Corresponding author: Patricio López-Jaramillo, MD PhD FACP, Director de Investigaciones, Fundación Oftalmológica de Santander, FOSCAL, Torre Milton Salazar, Primer piso, Calle 155A N. 23-09, El Bosque, Floridablanca, Santander, Colombia, Phone: +57-3153068939/57-7-6386000 Ext. 4165-4166, Fax: +57-7-6388108, E-mail: ; ; and Escuela de Medicina, Universidad de Santander, UDES, Bucaramanga, Colombia


1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28.10.1016/S0140-6736(05)66378-7Search in Google Scholar

2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356–9.10.1001/jama.287.3.356Search in Google Scholar

3. López-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. Socioeconomic pathology as a cause of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol 2007;60:168–78.10.1157/13099463Search in Google Scholar

4. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391–406.10.1146/annurev.nutr.24.012003.132155Search in Google Scholar

5. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.10.1161/CIRCULATIONAHA.109.192644Search in Google Scholar

6. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–23.10.1016/S0140-6736(10)60834-3Search in Google Scholar

7. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812–9.10.1016/j.amjmed.2006.02.031Search in Google Scholar PubMed

8. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403–14.10.1016/j.jacc.2006.09.032Search in Google Scholar PubMed

9. Lopez-Jaramillo P, Sanchez R, Diaz M, Cobos L, Bryce A, Parra-Carrillo JZ, Lizcano F, Lanas F, Sinay I, Sierra IV, Peñaherrera E, Bendersky M, Schmid H, Botero R, Urina M, Lara J, Foss MC, Marquez G, Harrap S, Ramirez AJ, Zanchetti A, on behalf of the Latin America expert Group. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens 2013;31:223–38.10.1097/HJH.0b013e32835c5444Search in Google Scholar PubMed

10. Türkoglu C, Duman BS, Günay D, Cagatay P, Ozcan R, Büyükdevrim AS. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. Obes Surg 2003;13:699–705.10.1381/096089203322509255Search in Google Scholar PubMed

11. Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, Thorpe RJ Jr, Jamrozik K, Calling S, Strand BH, Shipley MJ, for the BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300,000 persons. Arch Intern Med 2007;167:1720–8.10.1001/archinte.167.16.1720Search in Google Scholar

12. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327–32.10.1016/S1043-2760(00)00301-5Search in Google Scholar

13. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, Gallo P, di Gioia CR. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005;29:251–5.10.1016/j.cyto.2004.11.002Search in Google Scholar PubMed

14. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129–39.10.1016/j.mce.2009.08.018Search in Google Scholar PubMed

15. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173–94.10.2337/diacare.14.3.173Search in Google Scholar PubMed

16. Friedman JE, Dohm GL, Leggett-Frazier N, Elton CW, Tapscott EB, Pories WP, Caro JF. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest 1992;89:701–5.10.1172/JCI115638Search in Google Scholar PubMed PubMed Central

17. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985;61:917–25.10.1210/jcem-61-5-917Search in Google Scholar PubMed

18. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev 2008;29:777–822.10.1210/er.2008-0024Search in Google Scholar PubMed PubMed Central

19. López-Jaramillo P, Casas JP. Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists. J Hum Hypertens 2002;16(Suppl 1):34–7.10.1038/sj.jhh.1001339Search in Google Scholar PubMed

20. López-Jaramillo P, Casas JP. Blockade of endothelial enzymes: new therapeutic targets. J Hum Hypertens 2002;16(Suppl 1): 100–3.10.1038/sj.jhh.1001353Search in Google Scholar PubMed

21. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol 2000;10:263–70.10.1016/S1047-2797(00)00045-4Search in Google Scholar

22. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010;2010. doi:pii: 289645. 10.1155/2010/289645.10.1155/2010/289645Search in Google Scholar PubMed PubMed Central

23. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–7.10.1038/nature05488Search in Google Scholar PubMed

24. Rueda-Clausen CF, Lahera V, Calderón J, Bolivar IC, Castillo VR, Gutiérrez M, Carreño M, Oubiña Mdel P, Cachofeiro V, López-Jaramillo P. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol 2010;139:32–41.10.1016/j.ijcard.2008.09.005Search in Google Scholar PubMed

25. Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925–9.10.1210/jc.83.11.3925Search in Google Scholar

26. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, Kumar S. Insulin-mediated up regulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005;111:1954–61.10.1161/01.CIR.0000161954.17870.5DSearch in Google Scholar PubMed

27. de las Heras N, Martín-Fernández B, Miana M, Ballesteros S, Oubiña MP, López-Farré AJ, Cachofeiro V, Lahera V. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens Suppl 2009;27:37–41.10.1097/01.hjh.0000358836.64052.43Search in Google Scholar PubMed

28. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463–73.10.1097/01.hjh.0000160198.05416.72Search in Google Scholar PubMed

29. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004;13:325–32.10.1097/00041552-200405000-00010Search in Google Scholar PubMed

30. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie 2004;86:779–84.10.1016/j.biochi.2004.09.016Search in Google Scholar PubMed

31. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, Wallace AM, Sattar N. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007;191:418–26.10.1016/j.atherosclerosis.2006.04.012Search in Google Scholar

32. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004;89:3872–8.10.1210/jc.2003-031676Search in Google Scholar

33. Stefanović A, Kotur-Stevuljević J, Spasić S, Bogavac-Stanojević N, Bujisić N. The influence of obesity on the oxidative stress status and the concentration of leptin in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2008;79:156–63.10.1016/j.diabres.2007.07.019Search in Google Scholar

34. Abdella NA, Mojiminiyi OA, Moussa MA, Zaki M, Al Mohammedi H, Al Ozairi ES, Al Jebely S. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med 2005;22:278–85.10.1111/j.1464-5491.2004.01405.xSearch in Google Scholar

35. Uslu S, Kebapçi N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med 2012;4:113–20.10.3892/etm.2012.557Search in Google Scholar

36. Asakawa H, Tokunaga K, Kawakami F. Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2001;15:57–62.10.1016/S1056-8727(00)00145-8Search in Google Scholar

37. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984–2002. Diabet Med 2010;27:1004–11.10.1111/j.1464-5491.2010.03043.xSearch in Google Scholar PubMed

38. Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med 2011;9:25.10.1186/1741-7015-9-25Search in Google Scholar PubMed PubMed Central

39. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–9.10.1074/jbc.270.45.26746Search in Google Scholar PubMed

40. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–703.10.1074/jbc.271.18.10697Search in Google Scholar PubMed

41. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975–81.10.1253/circj.68.975Search in Google Scholar

42. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 2012;425:560–4.10.1016/j.bbrc.2012.08.024Search in Google Scholar

43. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226–8.10.1016/S0140-6736(03)12255-6Search in Google Scholar

44. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164–74.10.1093/aje/kwk001Search in Google Scholar PubMed PubMed Central

45. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318–23.10.1161/01.HYP.0000129281.03801.4bSearch in Google Scholar PubMed

46. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004;13:236–42.10.1080/08037050410021397Search in Google Scholar PubMed

47. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534–39.10.2337/diabetes.54.2.534Search in Google Scholar PubMed

48. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134–41.10.1681/ASN.V131134Search in Google Scholar PubMed

49. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc 2004;291:1730–7.10.1001/jama.291.14.1730Search in Google Scholar PubMed

50. Golledge J, Leicht A, Crowther RG, Clancy P, Spinks WL, Quigley F. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg 2007;45:40–6.10.1016/j.jvs.2006.09.006Search in Google Scholar PubMed

51. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, Funahashi T, Ogihara T, Kawano Y. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006;188:384–90.10.1016/j.atherosclerosis.2005.10.039Search in Google Scholar PubMed

52. Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care 2011;15:221.10.1186/cc10021Search in Google Scholar PubMed PubMed Central

53. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288–95.10.1038/nm788Search in Google Scholar PubMed

54. Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P, Resink TJ. T-cadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 2005;19:1737–9.10.1096/fj.05-3834fjeSearch in Google Scholar PubMed

55. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893–8.10.1161/01.CIR.0000018622.84402.FFSearch in Google Scholar PubMed

56. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–55.10.1079/BJN20041213Search in Google Scholar

57. Lenz A, Diamond FB Jr. Obesity: the hormonal milieu. Curr Opin Endocrinol Diabetes Obes 2008;15:9–20.10.1097/MED.0b013e3282f43a5bSearch in Google Scholar PubMed

58. Tian F, Luo R, Zhao Z, Wu Y, Ban Dj. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010;118:258–65.10.1055/s-0029-1237706Search in Google Scholar PubMed

59. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442–50.10.2337/diacare.26.8.2442Search in Google Scholar PubMed

60. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293–300.10.1530/eje.0.1480293Search in Google Scholar PubMed

61. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169–76.10.2337/diabetes.53.8.2169Search in Google Scholar

62. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312–19.10.1210/jc.2004-0190Search in Google Scholar

63. Shinmura K, Tamaki K, Saito K, Nakano Y, Tobe T, Bolli R. Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. Circulation 2007;116:2809–17.10.1161/CIRCULATIONAHA.107.725697Search in Google Scholar

64. Gómez-Arbeláez D, Lahera V, Oubiña P, Valero-Muñoz M, de Las Heras N, Rodríguez Y, García RG, Camacho PA, López-Jaramillo P. Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: a double-blind, placebo-controlled, randomized, crossover study. Mediators Inflamm 2013;2013:285795. doi: 10.1155/2013/285795.10.1155/2013/285795Search in Google Scholar

65. Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 2008;57:268–73.10.1016/j.metabol.2007.09.011Search in Google Scholar

66. Lawlor DA, Ebrahim S, Davey Smith G. Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. Br Med J 2001;323:541–5.10.1136/bmj.323.7312.541Search in Google Scholar

67. Lawlor DA, Smith GD, Leon DA, Sterne JA, Ebrahim S. Secular trends in mortality by stroke subtype in the 20th century: a retrospective analysis. Lancet 2002;360:1818–23.10.1016/S0140-6736(02)11769-7Search in Google Scholar

68. Heras M, Marrugat J, Arós F, Bosch X, Enero J, Suárez MA, Pabón P, Ancillo P, Loma-Osorio A, Rodríguez JJ, Subirana I, Vila J; en representación de los investigadores del estudio PRIAMHO. Reduction in acute myocardial infarction mortality over a five-year period. Rev Esp Cardiol 2006;59:200–8.10.1157/13086076Search in Google Scholar

69. López-Jaramillo P, Velandia-Carrillo C, Alvarez-Camacho J, Cohen DD, Sánchez-Solano T, Castillo-López G. Inflammation and hypertension: are there regional differences? Int J Hypertens 2013;2013:492094. doi: 10.1155/2013/492094.10.1155/2013/492094Search in Google Scholar PubMed PubMed Central

70. Simão AN, Lozovoy MA, Bahls LD, Morimoto HK, Simão TN, Matsuo T, Dichi I. Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide. Br J Nutr 2012;108:1435–42.10.1017/S0007114511006921Search in Google Scholar PubMed

71. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008;32:772–9.10.1038/sj.ijo.0803793Search in Google Scholar PubMed

72. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. Acta Med Indones 2010;42:187–91.Search in Google Scholar

73. Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM. Does obesity explain excess prevalence of diabetes among Mexican Americans? Results of the San Antonio Heart Study. Diabetologia 1983;24:272–7.10.1007/BF00282712Search in Google Scholar PubMed

74. Gardner LI Jr, Stern MP, Haffner SM, Gaskill SP, Hazuda HP, Relethford JH, Eifler CW. Prevalence of diabetes in Mexican Americans. Relationship to percent of gene pool derived from native American sources. Diabetes 1984;33:86–92.10.2337/diab.33.1.86Search in Google Scholar PubMed

75. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980–6.10.2337/db07-1419Search in Google Scholar PubMed PubMed Central

76. Pereira RI, Wang CC, Hosokawa P, Dickinson LM, Chonchol M, Krantz MJ, Steiner JF, Bessesen DH, Havranek EP, Long CS. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures. BMC Endocr Disord 2011;11:13.10.1186/1472-6823-11-13Search in Google Scholar PubMed PubMed Central

77. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism 2004;53:1–3.10.1016/j.metabol.2003.07.002Search in Google Scholar PubMed

Received: 2013-9-26
Accepted: 2013-11-20
Published Online: 2013-12-13
Published in Print: 2014-4-1

©2014 by De Gruyter